News and Announcements
Opal acquisition of Formulytica – Capital raising
- Published May 06, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Melbourne, 6 May 2021: Opal Biosciences Limited today announced its Information Memorandum to raise up to $5 million through the issue of 33,333,333 shares at $0.15 (15 cents) per share to fund the transaction costs associated with the acquisition of revenue-generating specialist pharmaceutical formulation developer, Formulytica Pty Ltd, fund the growth of Formulytica’s contract and innovative businesses, build a small batch sterile manufacture/GMP facility and provide Opal with general working capital to continue with the development and operation of Opal’s business.
The Offer under the Information Memorandum opens on 6 May 2021 and will close on 15 June 2021. These dates are indicative only and Opal reserves the rights to change the dates.
Opal’s expertise in discovery and early-through-to-late-stage development, clinical trials and marketing of innovative products and commercial successes will complement Formulytica’s in the new merged entity and will fill a significant gap in the value chain in Australian pharmaceutical product development.
The transaction will involve Opal’s acquisition of all the shares of Formulytica to form a wholly-owned subsidiary and the conversion of debt to equity. Formulytica will continue to operate under its trademark and remain on the premises of Ensign Laboratories, Mulgrave, Victoria. The transaction will be effective on the completion of a capital raising and Formulytica’s Peter Cox and Dr Richard Buchta will then join the Opal board.
The Offer under the Information Memorandum is subject to a minimum subscription amount of $2,000,000. If the minimum subscription amount is not reached, any application money received by Opal will be returned in full (without interest) to Applicants.
The Offer of shares pursuant to this Information Memorandum is only available to investors to whom an offer can be made without the need for a Disclosure Document to be provided under the Corporations Act 2001 (Cth). The Information Memorandum is not a prospectus or product disclosure document under the Corporations Act and has not been lodged with ASIC. The attention of potential investors is drawn to the Important Notice on pages 2-4 of the Information Memorandum.
About Opal Biosciences Ltd
Opal Biosciences is a preclinical stage Australian biotechnology company and an innovative player in infectious disease treatment. The unmet need for new anti-infectives is due to increasing resistance to existing antibiotics, more widespread and common difficult-to-treat infections, and the paucity of upcoming new treatments. This need has spurred the EU and US to introduce significant financial incentives to encourage the development of new anti-infectives.
About Formulytica Pty Ltd
Formulytica is an Australian innovative technology developer and service provider specialising in topical and injectable formulation development. Formulytica’s services include new product development and it specializes in the analytical science of semi-solid formulations for topical application utilised in dermatology, pharmaceutical, cosmetic, veterinary and personal care products, such as skincare and haircare. Formulytica’s injectable parenteral expertise covers solution and lipid-based formulations, in biologics, as well as small organic molecules.
Company Updates
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Reinventing the Condom: How an Australian Deep-Tech Startup Plans to Disrupt a $12 Billion Market
For more than half a century, the global condom industry has remained fundamentally unchanged, constrained by standard materials like latex and solid synthetic polymers. Despite widespread consumer demand for better alternatives, product design has treated the device strictly as a mechanical barrier, sacrificing feel for function. Sydney-based Eudaemon Technologies is setting out to upend that […]
Backed By Leading Investment Groups and Family Offices
